These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8865127)

  • 1. Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines.
    Viallet J; Tsao MS; Gallant G
    Lung Cancer; 1996 Aug; 15(1):93-101. PubMed ID: 8865127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
    Klaassen U; Harstrick A; Schleucher N; Vanhoefer U; Schröder J; Wilke H; Seeber S
    Br J Cancer; 1996 Jul; 74(2):224-8. PubMed ID: 8688325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
    Hahn SM; Liebmann JE; Cook J; Fisher J; Goldspiel B; Venzon D; Mitchell JB; Kaufman D
    Cancer; 1993 Nov; 72(9):2705-11. PubMed ID: 8104682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
    Fujimoto S; Chikazawa H
    Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
    Bible KC; Kaufmann SH
    Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Mori K; Yazawa Y; Tsunoda S
    Cancer Chemother Pharmacol; 1999; 44(5):381-8. PubMed ID: 10501911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines.
    Aoe K; Kiura K; Ueoka H; Tabata M; Matsumura T; Chikamori M; Matsushita A; Kohara H; Harada M
    Anticancer Res; 1999; 19(1A):291-9. PubMed ID: 10226557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
    Kalemkerian GP; Ou X
    Cancer Chemother Pharmacol; 1999; 43(2):145-50. PubMed ID: 9923820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of paclitaxel and etoposide in the treatment of lung cancer.
    Perez EA; Buckwalter CA; Reid JP
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):21-5. PubMed ID: 8996593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.
    Akutsu M; Kano Y; Tsunoda S; Suzuki K; Yazawa Y; Miura Y
    Eur J Cancer; 1995 Dec; 31A(13-14):2341-6. PubMed ID: 8652267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
    Tsai CM; Chen JT; Stewart DJ; Chiu CH; Lai CL; Hsiao SY; Chen YM; Chang KT
    J Thorac Oncol; 2011 Mar; 6(3):559-68. PubMed ID: 21258258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
    Bonomi P; Kim K; Fairclough D; Cella D; Kugler J; Rowinsky E; Jiroutek M; Johnson D
    J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
    Hand A; Pelin K; Halme M; Ekman A; Mattson M; Vallas M; Mattson K; Linnainmaa K; Husgafvel-Pursiainen K
    Anticancer Drugs; 1993 Jun; 4(3):365-8. PubMed ID: 8395259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
    Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
    Bunn PA
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):18-25. PubMed ID: 9007116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
    Rosell R; Felip E; Massuti B; González-Larriba JL; Benito D; López-Cabrerizo MP; Salamanca O; Camps C; Puerto-Pica J
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-56-S12-60. PubMed ID: 9331123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.